TY - JOUR
T1 - Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk
T2 - Results from the prostate cancer prevention trial
AU - Figg, William D.
AU - Chau, Cindy H.
AU - Price, Douglas K.
AU - Till, Cathee
AU - Goodman, Phyllis J.
AU - Cho, Yonggon
AU - Varella-Garcia, Marileila
AU - Reichardt, Juergen K.V.
AU - Tangen, Catherine M.
AU - Leach, Robin J.
AU - Van Bokhoven, Adrie
AU - Thompson, Ian M.
AU - Lucia, M. Scott
PY - 2014
Y1 - 2014
N2 - Objective To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. Methods This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. Results There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. Conclusion Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.
AB - Objective To investigate the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer containing TMPRSS2:ETS fusion genes. Methods This nested case-control study came from subjects enrolled in the Prostate Cancer Prevention Trial and included 195 biopsy-proven prostate cancer cases with a known TMPRSS2:ETS status and 1344 matched controls. Results There was no association between the CAG repeat length and the risk of TMPRSS2:ETS-positive (odds ratio, 0.97; 95% confidence interval, 0.91-1.04) or TMPRSS2:ETS-negative prostate cancer (odds ratio, 1.04; 95% confidence interval, 0.97-1.11) and in patients with low- or high-grade disease. Conclusion Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84903689279&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2014.03.015
DO - 10.1016/j.urology.2014.03.015
M3 - Article
C2 - 24824408
AN - SCOPUS:84903689279
SN - 0090-4295
VL - 84
SP - 127
EP - 131
JO - Urology
JF - Urology
IS - 1
ER -